Drawing from personal experience, Patty Keating advocates for greater awareness, improved diagnosis, and treatment among ...

Hypoparathyroidism (hypoPT) is an uncommon condition that happens when your body doesn’t make enough parathyroid hormone (PTH) or the blood levels of PTH are undetectable. How Do You Know If ...

It was a rough night for Patrick Mahomes at the 2025 Super Bowl. He threw a bunch of interceptions, got sacked a lot, and he ...

Expert Rev Endocrinol Metab. 2012;7(3):255-257. The future of hormone replacement therapy in hypoparathyroidism can be viewed with optimism, even if we are left with several unanswered questions ...

Hypoparathyroidism is a rare condition characterized by inadequate levels of parathyroid hormone (PTH) or resistance to PTH, leading to a wide range of health complications and reduced quality of ...

The global hypoparathyroidism treatment market is on the cusp of notable growth, according to a comprehensive analysis conducted by Future Market Insights. In 2022, the market was valued at USD 777.4 ...

Septerna has dosed the first subjects in a Phase I clinical trial of its investigational product SEP-786, being developed to ...

After turning it down a year ago, the FDA has cleared once-daily injectable Yorvipath for hypoparathyroidism from Ascendis Pharma. Yorvipath (palopegteriparatide) – previously known as TransCon ...

Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...

Considering taking supplements to treat hypoparathyroidism? Below is a list of common natural remedies used to treat or reduce the symptoms of hypoparathyroidism. Follow the links to read common ...

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Hypoparathyroidism. ORLANDO, FLORIDA / ACCESSWIRE / February 3, 2025 / The Assistance F ...

Cantor Fitzgerald reaffirmed its Overweight rating and $170.00 price target on Ascendis Pharma (NASDAQ:ASND) shares, currently trading at $119.49. The firm's analyst highlighted the early adoption of ...